News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
270,096 Results
Type
Article (14515)
Company Profile (283)
Press Release (255298)
Section
Business (80377)
Career Advice (178)
Deals (13399)
Drug Delivery (35)
Drug Development (50688)
Employer Resources (33)
FDA (5761)
Job Trends (5208)
News (145768)
Policy (10157)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (938)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21874)
ALS (60)
Alzheimer's disease (830)
Antibody-drug conjugate (ADC) (86)
Approvals (5773)
Artificial intelligence (109)
Autoimmune disease (10)
Automation (5)
Bankruptcy (106)
Best Places to Work (4610)
BIOSECURE Act (5)
Biosimilars (39)
Biotechnology (233)
Bladder cancer (43)
Brain cancer (19)
Breast cancer (139)
Cancer (1287)
Cardiovascular disease (104)
Career advice (152)
Career pathing (3)
CAR-T (109)
Cell therapy (307)
Cervical cancer (7)
Clinical research (41038)
Collaboration (501)
Compensation (218)
Complete response letters (13)
COVID-19 (1053)
CRISPR (36)
C-suite (143)
Cystic fibrosis (76)
Data (1340)
Denatured (11)
Depression (30)
Diabetes (124)
Diagnostics (1332)
Digital health (4)
Diversity (2)
Diversity, equity & inclusion (11)
Drug discovery (77)
Drug pricing (29)
Drug shortages (3)
Duchenne muscular dystrophy (81)
Earnings (29943)
Editorial (17)
Employer branding (4)
Employer resources (31)
Events (48550)
Executive appointments (396)
FDA (6382)
Featured Employer (32)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (472)
Gene editing (87)
Generative AI (9)
Gene therapy (227)
GLP-1 (359)
Government (1095)
Grass and pollen (2)
Guidances (19)
Healthcare (6691)
Huntington's disease (21)
IgA nephropathy (20)
Immunology and inflammation (80)
Indications (18)
Infectious disease (1116)
Inflammatory bowel disease (111)
Inflation Reduction Act (8)
Influenza (18)
Intellectual property (55)
Interviews (20)
IPO (7335)
IRA (12)
Job creations (891)
Job search strategy (145)
Kidney cancer (6)
Labor market (4)
Layoffs (207)
Leadership (2)
Legal (1421)
Liver cancer (30)
Lung cancer (185)
Lymphoma (81)
Machine learning (1)
Management (7)
Manufacturing (115)
MASH (47)
Medical device (2684)
Medtech (2685)
Mergers & acquisitions (6352)
Metabolic disorders (363)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (57)
Neuropsychiatric disorders (23)
Neuroscience (1195)
NextGen: Class of 2025 (2067)
Non-profit (887)
Northern California (1530)
Now hiring (21)
Obesity (186)
Opinion (102)
Ovarian cancer (59)
Pain (41)
Pancreatic cancer (51)
Parkinson's disease (104)
Partnered (6)
Patents (111)
Patient recruitment (66)
Peanut (35)
People (25732)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14478)
Phase II (19080)
Phase III (12086)
Pipeline (686)
Podcasts (46)
Policy (36)
Postmarket research (865)
Preclinical (6080)
Press Release (31)
Prostate cancer (52)
Psychedelics (35)
Radiopharmaceuticals (212)
Rare diseases (272)
Real estate (1444)
Recruiting (12)
Regulatory (8634)
Reports (16)
Research institute (962)
Resumes & cover letters (20)
Rett syndrome (3)
RNA editing (2)
RSV (10)
Schizophrenia (54)
Series A (92)
Series B (59)
Service/supplier (1)
Sickle cell disease (38)
Southern California (1359)
Special edition (11)
Spinal muscular atrophy (118)
Sponsored (11)
Startups (1985)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (33)
United States (12057)
Vaccines (222)
Venture capitalists (29)
Webinars (7)
Weight loss (107)
Women's health (15)
Worklife (2)
Date
Today (81)
Last 7 days (370)
Last 30 days (1622)
Last 365 days (20113)
2025 (4607)
2024 (20709)
2023 (22618)
2022 (27051)
2021 (28078)
2020 (23869)
2019 (16601)
2018 (12041)
2017 (13981)
2016 (12059)
2015 (14603)
2014 (10521)
2013 (7568)
2012 (7621)
2011 (7708)
2010 (7504)
Location
Africa (160)
Alabama (38)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17437)
Australia (2960)
California (3486)
Canada (1048)
China (319)
Colorado (136)
Connecticut (145)
Delaware (87)
Europe (37850)
Florida (408)
Georgia (107)
Idaho (18)
Illinois (216)
India (9)
Indiana (88)
Iowa (1)
Japan (69)
Kansas (59)
Kentucky (5)
Louisiana (3)
Maine (12)
Maryland (443)
Massachusetts (2765)
Michigan (69)
Minnesota (137)
Mississippi (1)
Missouri (23)
Montana (14)
Nebraska (5)
Nevada (15)
New Hampshire (14)
New Jersey (878)
New Mexico (12)
New York (956)
North Carolina (518)
North Dakota (4)
Northern California (1530)
Ohio (108)
Oklahoma (9)
Oregon (21)
Pennsylvania (667)
Puerto Rico (3)
Rhode Island (15)
South America (226)
South Carolina (4)
Southern California (1359)
Tennessee (25)
Texas (399)
Utah (48)
Virginia (67)
Washington D.C. (28)
Washington State (321)
Wisconsin (13)
270,096 Results for "horizon therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Spinal muscular atrophy
6 Therapies on the Horizon for Spinal Muscular Atrophy
Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several companies—including Novartis, Scholar Rock and Biogen—progressing novel candidates through clinical trials.
March 24, 2025
·
5 min read
·
Natalia Mesa
Press Releases
Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference
March 24, 2025
·
2 min read
Press Releases
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
February 7, 2025
·
5 min read
Press Releases
Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025
February 4, 2025
·
8 min read
Gene therapy
5 Cardio Gene Therapies on the Near Horizon
Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic for cardiovascular diseases including congestive heart failure, chronic refractory angina and cardiomyopathy.
January 13, 2025
·
9 min read
·
Tristan Manalac
Press Releases
IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor
March 26, 2025
·
7 min read
Press Releases
Expanding Horizons: Xentria Achieves Milestone Success with Biosimilar Development
January 8, 2025
·
3 min read
Press Releases
Theranexus Presents an Update of its Cash Position and Financing Horizon
December 17, 2024
·
4 min read
Deals
AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC
Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.
October 6, 2023
·
14 min read
Genetown
Nested Therapeutics to Present Preclinical Data for NST-628, a Novel Pan-RAF/MEK Molecular Glue, in the New Drugs on the Horizon Series at 2024 AACR Annual Meeting
Nested Therapeutics today announced that preclinical data from its lead program, NST-628, will be featured in an oral presentation in the “New Drugs on the Horizon” series at the American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 5-10, 2024.
March 28, 2024
·
2 min read
1 of 27,010
Next
